Oppenheimer Increases Alimera Sciences PT

Oppenheimer increased its Alimera Sciences

price target from $4 to $7 in a research report published today. In the report, Oppenheimer stated, "We believe ALIM is leaning toward a commercialization partnership, which would bring in needed capital near-term. We believe ALIM is substantially undervalued on Iluvien's E.U. opportunity." Shares of Alimera Sciences closed today at $3.94, up 70.56% from Monday's market close.